Aeterna Zentaris (AEZS) Stock Price, News & Analysis

Company Overview

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $3.25 to $3.46
• 50-Day Range: $3.04 to $3.90
• 52-Week Range: $3.96 to $12.00
• Volume: 3,463 shs
• Average Volume: 7,305 shs
• Market Capitalization: $6.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AEZS Stock Analysis - Frequently Asked Questions

How have AEZS shares performed this year?

Aeterna Zentaris' stock was trading at $2.77 on January 1st, 2025. Since then, AEZS shares have increased by 22.7% and is now trading at $3.40.
View the best growth stocks for 2025 here.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $1.00. The biopharmaceutical company earned $0.60 million during the quarter, compared to analysts' expectations of $0.60 million. Aeterna Zentaris had a negative trailing twelve-month return on equity of 83.45% and a negative net margin of 760.32%.

When did Aeterna Zentaris' stock split?

Aeterna Zentaris shares reverse split before market open on Friday, May 3rd 2024.The 1-4 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aeterna Zentaris own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Tonix Pharmaceuticals (TNXP), Bausch Health Cos (BHC), Ford Motor (F), DarioHealth (DRIO), Acasti Pharma (ACST), Onconova Therapeutics (ONTX) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 7/01/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AEZS
• CIK: 1113423
• Web: www.zentaris.com
• Phone: (418) 652-8525
• Fax: 418-948-9191
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($14.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.55 million
• Net Margins: -760.32%
• Pretax Margin: -760.28%
• Return on Equity: -83.45%
• Return on Assets: -45.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.94
• Quick Ratio: 5.93

Sales & Book Value

• Annual Sales: $2.37 million
• Price / Sales: 2.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.99 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 1,793,000
• Free Float: 1,791,000
• Market Cap: $6.10 million
• Optionable: No Data
• Beta: 1.55